Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01032200 · ClinicalTrials.gov registry record · Phase 2
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01032200 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 54 participants.
The verdict
NCT01032200, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain. PURPOSE: This clinical trial is studying how well armodafinil works in treating fatigue caused by radiation therapy in patients with primary brain tumors.
Interventions
- OTHER placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2013-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01032200
The ClinicalTrials.gov registry entry for NCT01032200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01032200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01032200 about?
NCT01032200 is a clinical study titled "Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors". RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain. PURPOSE: This clinical trial is studying how well armodafinil works in treating fatigue caused by radiation therapy in patients with primary brain tumors.
What is the current status of trial NCT01032200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2010-08-01. Estimated completion is 2013-01-08.
What interventions are being tested in trial NCT01032200?
The interventions under investigation include: placebo (OTHER), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT01032200?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.